ADVERTISEMENT

Psychedelics News

Industry

Culture, Industry, Psychedelic Groundbreakers

10 Oct 2025

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

In the wake of Gilgamesh’s billion-dollar exit, a new wave of companies is emerging, smaller, stealthier, and far more scientifically disciplined than their first-wave predecessors. Their mission: harness the therapeutic...

By Madison Roberts

Breaking News, Health & Wellness, Industry, Psychedelic Groundbreakers, Psychedelic Titans, Science

18 Aug 2025

Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets

But while traditional psychedelic developers dominate headlines, Enveric Biosciences (NASDAQ: ENVB) has stayed quietly in the background, focusing on an equally groundbreaking, but less flashy, approach: non-hallucinogenic neuroplastogens, small molecules...

By Madison Roberts

Breaking News, Industry, Press Releases, Psychedelic Groundbreakers, Science

23 Jul 2025

Enveric’s Latest Patent Signals a Clear Path Forward for PTSD Drug Development

This week, Enveric announced it has received a second U.S. patent allowance for compounds in its EVM401 Series, expanding its growing intellectual property fortress. These aren’t just any molecules —...

By Madison Roberts

Breaking News, Health & Wellness, Industry, Press Releases, Psychedelic Groundbreakers, Psychedelic Titans, Science

15 Jul 2025

Enveric’s EB-003 Shows Promise in PTSD Model, Offering a New Direction in Trauma Treatment

Enveric Biosciences announced that its lead compound, EB-003, significantly reduced trauma-related fear behaviors in a preclinical PTSD model—highlighting its potential as a fast-acting, non-hallucinogenic treatment for a condition with few...

By Madison Roberts

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

20 May 2025

Enveric Biosciences Stakes Its Claim in Neurodegeneration Market

Enveric Biosciences is quietly making a bold move into the neurodegenerative disease space with a new class of molecules targeting the critical BDNF/TrKB pathway. While still in early stages, this...

By Madison Roberts

Industry

8 Apr 2025

No More Silence: The Opioid Epidemics Alarming Impact on Women

Women are facing a silent crisis in the opioid epidemic, with overdose deaths among women aged 30–64 skyrocketing by 260% since 1999. Beyond the statistics lie the stories of mothers,...

By Madison Roberts

Industry, Psychedelic Titans, Science

31 Mar 2025

The Future of Psychedelics: Why Next-Generation Molecules Will Win

The psychedelic industry is undergoing a major transformation. With new, non-hallucinogenic compounds on the rise, companies like Enveric Biosciences, Delix Therapeutics, and Gilgamesh Pharmaceuticals are leading the way in developing...

By Madison Roberts

Industry

1 Jan 2025

The Psychedelic Industry in 2025: A New Era of Healing and Transformation

The psychedelic industry is poised for groundbreaking advancements in 2025, from new clinical applications to state-level regulatory frameworks. Experts highlight the potential for treating PTSD, depression, and addiction while addressing...

By Madison Roberts

Industry

3 Dec 2024

Enveric Biosciences Receives Two US Patents for Psilocybin Derivatives

Enveric Biosciences announced two new patents from the USPTO for its EVM301 and EVM201 series, boosting its total patents to 11 for EVM301. These patents safeguard groundbreaking psilocybin derivatives and...

By Madison Roberts

ADVERTISEMENT

Follow us on social

Latest News

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads